Status:
TERMINATED
Quetiapine in Postpartum Depression
Lead Sponsor:
AstraZeneca
Conditions:
Postpartum Depressive Disorder
Eligibility:
FEMALE
18-39 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate the efficacy and tolerability of quetiapine in female patients with postpartum depressive disorder with psychotic symptoms
Eligibility Criteria
Inclusion
- Provision of signed informed consent.
- Female patients with severe postpartum depressive disorders with psychotic symptoms and a minimum HAM-D cut off score of 20 points
Exclusion
- Woman with pre-existing psychotic disorder
- Patients with alcohol or substance abuse or dependence
- Patients who pose an imminent risk of suicide or danger to self or others
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00681668
Start Date
August 1 2007
End Date
October 1 2008
Last Update
December 21 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Herten, Westfalen-Lippe, Germany